Clinical trials: Histological Type of Neoplasm
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Liver Diseases
Liver Diseases: Extracellular Vesicles as Biomarkers
Worldwide, cirrhosis is responsible for 2 million deaths per year. Hepatocellular carcinoma (HCC) accounts for 800,000 of these deaths and is the 3rd leading cause of cancer related death.
- Trial name
- LIVER-TRACK (NCT07185360)
- Testing
- blood sampling for volunteers, blood sampling for diabetics patients with F3/F4 fibrosis, blood sampling for patients with liver disease
- Where
- France
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma
Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.
This trial is set up as a prospective observational cohort study to identify if either biopsy or resection should be the surgical modality of choice in elderly glioblastoma patients with a newly diagnosed tumor.
- Trial name
- BIOPSY (NCT05641220)
- Where
- 6 sites in Netherlands
- Volunteers
- 325 people
- Sponsor
- Erasmus Medical Center
Multiple Myeloma
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the efficacy of lenalidomide plus low-dose dexamethasone in Chinese subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT01593410
- Testing
- Lenalidomide, Dexamethasone
- Where
- 13 sites in China
- Volunteers
- 194 people
- Sponsor
- Celgene
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Trial name
- NCT00098813
- Testing
- romidepsin, laboratory biomarker analysis, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenomatous Polyposis Coli
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).
- Trial name
- NCT05014360
- Testing
- JNJ-64251330
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC
Diffuse Large B-cell Lymphoma
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in patients affected by relapsed/refractory DLBCL…
- Trial name
- NCT04433182
- Testing
- Copanlisib
- Where
- 17 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
The purpose of this study is to find the optimal dose of trabectedin for Chinese patients with locally advanced or metastatic L-sarcoma (liposarcoma or leiomyosarcoma) who were previously treated (in any order) with at least an…
- Trial name
- NCT01692678
- Testing
- Trabectedin, Dacarbazine
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Mycosis Fungoides
Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides
The purpise of this study was to determine the effect of low-dose (4 Gy) total skin electron beam therapy as a second-line treatment of stage IB-II mycosis fungoides.
- Trial name
- NCT00496743
- Testing
- Low-dose total skin electron beam therapy (4 Gy)
- Volunteers
- 10 people
- Sponsor
- Bispebjerg Hospital
Chronic Lymphocytic Leukemia
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
- Trial name
- NCT00836043
- Testing
- Alemtuzumab (MabCampath)
- Where
- 3 sites in Bosnia and Herzegovina, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Genzyme, a Sanofi Company
Esophagus SCC
Neoadjuvant Immunotherapy to ESCC
Currently, surgery after neoadjuvant chemoradiotherapy is the standard treatment for patients with locally advanced esophageal cancer, but the recurrence rate is high and the 5-year survival rate is low.
- Trial name
- NCT04625543
- Testing
- Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin
- Where
- China
- Sponsor
- Qilu Hospital of Shandong University
Acute Myeloid Leukemia
Gamma Delta T Cells in AML
The Royal Marsden NHS Foundation Trust is committed to improving patient experience; this research is being undertaken to try to develop a novel treatment for patients with Acute Myeloid Leukaemia (AML).
- Trial name
- NCT03885076
- Testing
- Blood collection and bone marrow aspirate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Renal Cell Carcinoma
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
Cancer immunotherapy has been largely adopted in oncology patient management in the last decade. The deep and long responses to immunotherapy have accelerated the approval of these drugs across multiple disease sites.
- Trial name
- PERFORM (NCT04163289)
- Testing
- Fecal Microbiota Transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse…
- Trial name
- NCT03605550
- Testing
- PTC596, Radiotherapy
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nationwide Children's Hospital
Carcinoma, Squamous Cell, Head and Neck Neoplasms
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
The purpose of this study is to determine the safety and efficacy of an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 6636) as a single agent in Adult Patients With Squamous Cell Carcinoma of the Head \& Neck and…
- Trial name
- NCT00073450
- Testing
- Farnesyl Protein Transferase Inhibitor
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Study of the Angiogenesis by PET/CT in Patients With Lymphoma
The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass
- Trial name
- RGDLymphome (NCT02490891)
- Testing
- RGD K5 PET scan
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Centre Henri Becquerel
Metastatic Melanoma
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy
The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma after 2…
- Trial name
- TEP-ANTI-PD1 (NCT03888950)
- Testing
- FDG PET-CT
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
- Trial name
- ALT-101 (NCT07586618)
- Testing
- 4A10
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Allterum Therapeutics, Inc
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic…
- Trial name
- FIDES-01 (NCT03230318)
- Testing
- derazantinib
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 148 people
- Sponsor
- Basilea Pharmaceutica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.